SYS-CON MEDIA Authors: Stackify Blog, Zakia Bouachraoui, Yeshim Deniz, Elizabeth White, Pat Romanski

News Feed Item

Savara Submits Investigational New Drug Application to FDA for Expansion of Molgradex Impala Study Into U.S.

AUSTIN, TX--(Marketwired - December 21, 2017) - Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead product Molgradex, an inhaled formulation of recombinant human GM-CSF, for the treatment of autoimmune pulmonary alveolar proteinosis, or PAP.

Earlier this year, the Company announced its expedited U.S. development strategy for Molgradex, which expanded and modified the ongoing IMPALA study in PAP to serve as a global pivotal study for U.S. registration purposes. The IMPALA study has progressed steadily, with more than 80% of the 90 patients now enrolled. With the recent IND submission, Savara plans to open U.S. sites and complete enrollment with patients from all major territories, including the U.S., EU, and Japan.

The IND submission also adds a blinded interim check of the variability of key secondary endpoints. This is designed to provide an opportunity to confirm or modify the study sample size, if necessary.

About the IMPALA Study

The IMPALA study is a randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of Molgradex with placebo in patients with PAP. The study began enrolling patients in Europe and Japan last year.

The primary endpoint in the IMPALA study is the absolute change from baseline in arterial-alveolar oxygen gradient, a measure of patient's oxygenation status, following 24 weeks of treatment. In addition, the FDA will focus its review on three key secondary endpoints that will be assessed to show improvement in clinical symptoms and function, including six-minute walk distance, St. George's respiratory questionnaire, and the time to need of whole lung lavage. Patients are randomized to receive treatment for up to 24 weeks in one of three treatment arms: 1) Molgradex 300 µg administered once daily, 2) Molgradex 300 µg and matching placebo administered daily in 7-day intermittent cycles of each, or 3) inhaled placebo administered once daily.

About Pulmonary Alveolar Proteinosis (PAP)

PAP is a rare lung disease which is characterized by the build-up of lung surfactant in the alveoli, or air sacs, of the lungs. The surfactant consists of proteins and lipids, and is an important physiological substance that lines the inside of the alveoli to prevent the lungs from collapsing. In a healthy lung, the old and inactivated surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by GM-CSF to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering the macrophages unable to perform their tasks. As a result, an excess of surfactant accumulates in the alveoli, causing obstruction of gas exchange, and patients start to experience shortness of breath, and decreased exercise tolerance. Patients may also experience chronic cough, as well as episodes of fever, chest pain, or coughing blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for lung transplant.

About Molgradex

Molgradex is an inhaled formulation of recombinant human GM-CSF, in Phase 3 development for PAP and in preparation for Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection. Molgradex has been granted Orphan Drug Designation for the treatment of PAP in the United States and the European Union.

About Savara

Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in preparation for Phase 2a development for NTM lung infection; AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis; and, Aironite, an inhaled sodium nitrite for heart failure with preserved ejection fraction, or HFpEF, in Phase 2 development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

Forward Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements relating to that the IMPALA study has progressed steadily, plans to open U.S. sites and complete enrollment with patients from all major territories, providing an opportunity to confirm or modify the study sample size and our strategy. Savara may not actually achieve any of the matters referred to in such forward looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the outcome of our ongoing clinical trials for our product candidates (including the expanded IMPALA study), the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs (including our expanded IMPALA study), the ability to obtain the necessary patient enrollment for our product candidates in a timely manner (including our expanded IMPALA study), the ability to successfully develop our product candidates, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as Molgradex, AeroVanc and Aironite that are safe and effective for use as human therapeutics and the timing and ability of Savara to raise additional equity capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Contacts:

Savara:
Ioana C. Hone
([email protected])
(512) 961-1891

For IR: The Trout Group
Kelly Mueller
([email protected])
(646) 378-2965

For Media: LaVoieHealthScience
Sharon Correia
([email protected])
(617) 412-8779

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Here to help unpack insights into the new era of using containers to gain ease with multi-cloud deployments are our panelists: Matt Baldwin, Founder and CEO at StackPointCloud, based in Seattle; Nic Jackson, Developer Advocate at HashiCorp, based in San Francisco, and Reynold Harbin, Director of Product Marketing at DigitalOcean, based in New York. The discussion is moderated by Dana Gardner, principal analyst at Interarbor Solutions.
Atmosera delivers modern cloud services that maximize the advantages of cloud-based infrastructures. Offering private, hybrid, and public cloud solutions, Atmosera works closely with customers to engineer, deploy, and operate cloud architectures with advanced services that deliver strategic business outcomes. Atmosera's expertise simplifies the process of cloud transformation and our 20+ years of experience managing complex IT environments provides our customers with the confidence and trust tha...
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
GCP Marketplace is based on a multi-cloud and hybrid-first philosophy, focused on giving Google Cloud partners and enterprise customers flexibility without lock-in. It also helps customers innovate by easily adopting new technologies from ISV partners, such as commercial Kubernetes applications, and allows companies to oversee the full lifecycle of a solution, from discovery through management.
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
Using serverless computing has a number of obvious benefits over traditional application infrastructure - you pay only for what you use, scale up or down immediately to match supply with demand, and avoid operating any server infrastructure at all. However, implementing maintainable and scalable applications using serverless computing services like AWS Lambda poses a number of challenges. The absence of long-lived, user-managed servers means that states cannot be maintained by the service. Lo...
Using serverless computing has a number of obvious benefits over traditional application infrastructure - you pay only for what you use, scale up or down immediately to match supply with demand, and avoid operating any server infrastructure at all. However, implementing maintainable and scalable applications using serverless computing services like AWS Lambda poses a number of challenges. The absence of long-lived, user-managed servers means that states cannot be maintained by the service. Lo...
With the new Kubernetes offering, ClearDATA solves one of the largest challenges in healthcare IT around time-to-deployment. Using ClearDATA's Automated Safeguards for Kubernetes, healthcare organizations have access to the container orchestration to dynamically deploy new containers on demand, monitor the health of each container for threats and seamlessly roll back faulty application updates to a previous version, avoid system-wide downtime and ensure secure continuous access to patient data.
With the rise of Docker, Kubernetes, and other container technologies, the growth of microservices has skyrocketed among dev teams looking to innovate on a faster release cycle. This has enabled teams to finally realize their DevOps goals to ship and iterate quickly in a continuous delivery model. Why containers are growing in popularity is no surprise — they’re extremely easy to spin up or down, but come with an unforeseen issue. However, without the right foresight, DevOps and IT teams may lo...
Docker and Kubernetes are key elements of modern cloud native deployment automations. After building your microservices, common practice is to create docker images and create YAML files to automate the deployment with Docker and Kubernetes. Writing these YAMLs, Dockerfile descriptors are really painful and error prone.Ballerina is a new cloud-native programing language which understands the architecture around it - the compiler is environment aware of microservices directly deployable into infra...
Signs of a shift in the usage of public clouds are everywhere. Previously, as organizations outgrew old IT methods, the natural answer was to try the public cloud approach; however, the public platform alone is not a complete solution. Complaints include unpredictable/escalating costs and mounting security concerns in the public cloud. Ultimately, public cloud adoption can ultimately mean a shift of IT pains instead of a resolution. That's why the move to hybrid, custom, and multi-cloud will ...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
10ZiG Technology is a leading provider of endpoints for a Virtual Desktop Infrastructure environment. Our fast and reliable hardware is VMware, Citrix and Microsoft ready and designed to handle all ranges of usage - from task-based to sophisticated CAD/CAM users. 10ZiG prides itself in being one of the only companies whose sole focus is in Thin Clients and Zero Clients for VDI. This focus allows us to provide a truly unique level of personal service and customization that is a rare find in th...